“HER2 Breast Cancer Talk”: A Review of Data from the SABCS 2020 Virtual Symposium - Episode 1

Current Treatment Landscape for HER2+ Breast Cancer

January 25, 2021
Ruth O'Regan, MD, University of Rochester Medical Center

Joyce O'Shaugnessy, MD, Texas Oncology

Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center

Debu Tripathy, MD, MD Anderson Cancer Center

Breast cancer experts discuss the evolution of HER2-targeted treatments, including margetuximab, trastuzumab, tucatinib, and neratinib, along with unmet needs in patients with HER2+ breast cancer.